



March 18, 2024

Kellie Moore

Dear Kellie Moore:

Thank you for your recent inquiry about ROLVEDON® (eflapegrastim-xnst).

Rolvedon (eflapegastrim) was approved by FDA in September of 2022 under the BLA number 761148. The BLA was approved based on data from two Phase 3 clinical trials in early-stage breast cancer. Rolontis is a legacy commercial name that is no longer in use.

We hope you find this information helpful. If you have further questions, please don't hesitate to contact Assertio Therapeutics Medical Information at 1-866-458-6389 from 9:00 am to 7:00 pm EST, Monday through Friday or via email at medinfo@assertiotx.com.

Sincerely,

Medical Information
Assertio Therapeutics, Inc.

2024-0049577

Enclosure(s):
Rolvedon Prescribing Information